英文名称:ChidamideTablets 【成份】 西达本胺。 【性状】 本品为类白色片。 【适应症】 西达本胺片适用于既往至少接受过一次全身化疗的复发或难治的外周T细胞淋巴瘤(PTCL)患者。该适应症是基于一项单臂临床试验的客观缓解率结果给予的有条件批准。有关本品用药后长期生存方面的获益尚未得到证实,随机对照设计的确证性...
通用名称:西达本胺片 商品名称:爱谱沙 英文名称:ChidamideTablets 【成份】 西达本胺。 【性状】 本品为类白色片。 【适应症】 西达本胺片适用于既往至少接受过一次全身化疗的复发或难治的外周T细胞淋巴瘤(PTCL)患者。该适应症是基于一项单臂临床试验的客观缓解率结果给予的有条件批准。有关本品用药后长期生存方面...
In Jun. 2024, Chidamide tablets were granted a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). The proposed indication is for Chidamide in combination with sintilimab and bevacizumab for the treatment of patien...
Chidamide tablets in 5 mg were provided by Chipscreen Biosciences Ltd. The study (ChiCTR-TNC-10000811) was conducted in accordance with the Declaration of Helsinki and approved by individual ethic committees of all the participated hospitals. All patients have signed informed consent before joined in...
enteric-coated excipient is greatly improved, while adverse reactions caused by a drug in the gastrointestinal tract are reduced; in addition, the dosage may be reduced while maintaining the curative effect, thus having more important clinical significance than commercially available chidamide tablets.LU...
SHENZHEN, China, Jan. 09, 2015 /PRNewswire/ -- Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
SHENZHEN, China, Nov. 29, 2019 /PRNewswire/ -- National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication